Stock listing
NASDAQ:KRRO Korro Bio, Inc. Stock
Home listing (NASDAQ) of Korro Bio, Inc.
Follow Korro Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:KRRO
$12.18 USD -0.26 (-2.1%)
Close on Nov 20, 2026
- Day range
- $12.01 – $12.95 USDNov 20, 2026
- Volume
- 123,520 sharesNov 20, 2026
- Market cap
- $179.4M USDAt the close on Nov 20, 2026 · price × 14.73M shares outstanding
- 52-week range
- $5.20 – $17.35 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.21M USDMedian day 147,684 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KRRO · Home | $12.18 USD | -0.26 (-2.1%) | 123,520 | $12.03 | $12.95 | $12.01 | $12.44 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KRRO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $12.18 | -0.26 | -2.1% | $12.03 | $12.95 | $12.01 | 123,520 | |
| $12.44 | +0.12 | +1.0% | $12.19 | $13.34 | $11.85 | 158,098 | |
| $12.32 | -0.39 | -3.1% | $12.69 | $13.22 | $12.15 | 158,229 | |
| $12.71 | -0.90 | -6.6% | $13.44 | $13.61 | $12.60 | 98,156 | |
| $13.61 | -0.70 | -4.9% | $14.24 | $14.24 | $13.19 | 78,960 | |
| $14.31 | -0.10 | -0.7% | $14.23 | $14.67 | $13.77 | 203,997 | |
| $14.41 | -1.32 | -8.4% | $15.70 | $15.70 | $14.10 | 192,691 | |
| $15.73 | +0.77 | +5.1% | $14.77 | $16.00 | $14.77 | 199,161 | |
| $14.96 | +0.21 | +1.4% | $15.14 | $16.00 | $14.52 | 175,617 | |
| $14.75 | +0.02 | +0.1% | $14.74 | $15.74 | $14.69 | 122,598 | |
| $14.73 | -1.89 | -11.4% | $16.00 | $16.00 | $11.50 | 436,189 | |
| $16.62 | +0.76 | +4.8% | $15.93 | $17.00 | $15.93 | 263,576 | |
| $15.86 | +0.015 | +0.1% | $15.89 | $17.35 | $15.55 | 426,691 | |
| $15.85 | +1.53 | +10.7% | $14.31 | $15.90 | $14.00 | 206,732 | |
| $14.32 | +0.115 | +0.8% | $13.99 | $14.55 | $13.41 | 130,745 | |
| $14.20 | +0.34 | +2.5% | $13.86 | $14.28 | $13.65 | 147,684 | |
| $13.86 | +0.56 | +4.2% | $13.18 | $14.11 | $13.04 | 269,308 | |
| $13.30 | +1.28 | +10.6% | $12.73 | $13.95 | $12.41 | 322,652 | |
| $12.02 | +0.04 | +0.3% | $11.96 | $12.30 | $11.53 | 183,157 | |
| $11.98 | -0.07 | -0.6% | $12.04 | $12.49 | $11.28 | 237,437 | |
| $12.05 | +2.76 | +29.7% | $9.40 | $12.10 | $9.085 | 476,475 | |
| $9.29 | -0.15 | -1.6% | $9.47 | $9.77 | $9.22 | 115,999 | |
| $9.44 | +0.53 | +5.9% | $8.92 | $9.63 | $8.92 | 235,039 | |
| $8.91 | +0.42 | +4.9% | $8.58 | $8.94 | $8.36 | 134,873 | |
| $8.49 | -0.82 | -8.8% | $9.32 | $9.38 | $8.45 | 129,734 | |
| $9.31 | +0.43 | +4.8% | $8.93 | $9.78 | $8.53 | 440,177 | |
| $8.88 | +0.07 | +0.8% | $8.62 | $9.13 | $8.34 | 216,497 | |
| $8.81 | -0.56 | -6.0% | $9.37 | $9.39 | $8.545 | 263,653 | |
| $9.37 | -0.79 | -7.8% | $10.09 | $10.26 | $9.32 | 140,406 | |
| $10.16 | -0.42 | -4.0% | $10.60 | $10.78 | $10.13 | 133,510 | |
| $10.58 | +0.09 | +0.9% | $10.36 | $10.64 | $10.18 | 167,311 | |
| $10.49 | +0.73 | +7.5% | $9.64 | $10.64 | $9.50 | 156,998 | |
| $9.76 | -0.21 | -2.1% | $10.20 | $10.35 | $9.47 | 142,620 | |
| $9.97 | +0.33 | +3.4% | $9.70 | $10.10 | $9.41 | 112,218 | |
| $9.64 | -0.07 | -0.7% | $9.90 | $9.90 | $9.478 | 153,134 | |
| $9.71 | -0.20 | -2.0% | $9.93 | $10.27 | $9.465 | 88,781 | |
| $9.91 | +0.35 | +3.7% | $9.89 | $10.01 | $9.50 | 108,137 | |
| $9.56 | +0.05 | +0.5% | $9.56 | $9.80 | $9.30 | 92,876 | |
| $9.51 | -0.06 | -0.6% | $9.49 | $9.655 | $9.24 | 132,438 | |
| $9.57 | 0.00 | 0.0% | $9.64 | $9.64 | $9.40 | 114,420 | |
| $9.57 | -0.26 | -2.6% | $9.71 | $9.75 | $9.41 | 197,457 | |
| $9.83 | -0.51 | -4.9% | $10.31 | $10.31 | $9.55 | 224,715 | |
| $10.34 | +0.36 | +3.6% | $10.08 | $10.58 | $10.01 | 213,478 | |
| $9.98 | -0.04 | -0.4% | $10.12 | $10.77 | $9.86 | 290,519 | |
| $10.02 | -1.78 | -15.1% | $11.71 | $11.95 | $9.505 | 763,397 | |
| $11.80 | -2.03 | -14.7% | $14.18 | $14.36 | $11.76 | 400,440 | |
| $13.83 | -0.24 | -1.7% | $14.15 | $14.86 | $13.44 | 304,657 | |
| $14.07 | +0.19 | +1.4% | $13.87 | $14.20 | $12.98 | 162,602 | |
| $13.88 | +0.07 | +0.5% | $13.59 | $15.15 | $13.56 | 264,804 | |
| $13.81 | +0.75 | +5.7% | $13.28 | $14.06 | $13.17 | 197,974 | |
| $13.06 | +0.13 | +1.0% | $12.80 | $13.16 | $12.38 | 145,795 | |
| $12.93 | -0.58 | -4.3% | $13.44 | $13.76 | $12.87 | 131,501 | |
| $13.51 | +1.27 | +10.4% | $12.03 | $13.62 | $11.89 | 119,120 | |
| $12.24 | +0.62 | +5.3% | $11.53 | $12.30 | $11.53 | 78,430 | |
| $11.62 | -0.35 | -2.9% | $12.09 | $12.63 | $11.30 | 82,728 | |
| $11.97 | -0.27 | -2.2% | $12.26 | $12.78 | $11.82 | 81,069 | |
| $12.24 | -0.25 | -2.0% | $12.57 | $12.64 | $12.14 | 59,005 | |
| $12.49 | -0.42 | -3.3% | $12.78 | $13.04 | $12.28 | 87,957 | |
| $12.91 | -0.35 | -2.6% | $13.13 | $13.55 | $12.80 | 67,368 | |
| $13.26 | -0.42 | -3.1% | $13.62 | $13.69 | $13.24 | 48,569 | |
| $13.68 | -0.05 | -0.4% | $13.71 | $13.98 | $13.23 | 41,275 | |
| $13.73 | +0.66 | +5.0% | $13.14 | $13.90 | $13.14 | 79,709 | |
| $13.07 | -0.11 | -0.8% | $13.18 | $13.60 | $12.66 | 70,368 | |
| $13.18 | +0.22 | +1.7% | $13.02 | $13.56 | $13.02 | 45,706 | |
| $12.96 | -0.99 | -7.1% | $13.77 | $13.77 | $12.83 | 64,120 |
Splits
1 split · NASDAQ:KRRO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-50 | Consolidation |
- Ticker
- NASDAQ:KRRO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Korro to Participate in Upcoming Investor Conferences
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 26 slides
Latest news
Korro to Participate in Upcoming Investor Conferences
Nov 19, 2026
Closed $12.18 (-2.1%) on Nov 20, 2026
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 13, 2026
Closed $12.71 (-6.6%) on Nov 16, 2026
Korro to Present at the 2026 Jefferies Global Healthcare Conference in London
Nov 6, 2026
Closed $14.75 (+0.1%) on Nov 6, 2026
Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026
Closed $14.73 (-11.4%) on Nov 5, 2026
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Oct 22, 2026
Closed $12.05 (+29.7%) on Oct 22, 2026
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 16, 2026
Closed $8.91 (+4.9%) on Oct 19, 2026
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Oct 5, 2026
Closed $9.76 (-2.1%) on Oct 6, 2026
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 6, 2026
Closed $12.12 (+5.4%) on Aug 6, 2026
Korro to Present at the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Closed $13.76 (+11.6%) on May 27, 2026
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency
May 20, 2026
Closed $10.01 (+9.4%) on May 20, 2026
Korro Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 109 in all · newest Nov 19, 2026 · oldest 2019
- Decks
- 6 decks · latest August 2026
Where Korro Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KRRO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KRRO | BOATS | United States | USD |
Valuation
EV/sales 57.6× against a median of 15.6×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $74.36M USD
- P/E
- Loss
- EV/sales
- 57.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.46
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Korro Bio, Inc. · NASDAQ:KRRO | US$179.4M | US$74.36M | n/a | 57.6× | n/a | 2.0× | n/a | 0.0× | 1.46 |
| Inventage Lab, Inc. · KRX:389470 | US$185.9M | US$113.3M | n/a | 61.3× | n/a | 2.8× | −127.0% | 0.2× | n/a |
| Inhibikase Therapeutics, Inc. · NASDAQ:IKT | US$185.2M | −US$8.17M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 1.50 |
| Antengene Corporation Limited · HKEX:6996 | US$183.1M | US$107.1M | n/a | 6.8× | n/a | 1.3× | −227.0% | 0.3× | n/a |
| Whitehawk Therapeutics, Inc. · NASDAQ:WHWK | US$181.2M | US$11.70M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | 1.35 |
| Sol-Gel Technologies Ltd. · NASDAQ:SLGL | US$180.6M | US$137.0M | n/a | 95.4× | n/a | 4.2× | n/a | 0.0× | 0.67 |
| Tanvex BioPharma, Inc. · TWSE:6541 | US$180.5M | US$225.7M | n/a | 11.3× | n/a | 1.2× | −222.8% | 0.4× | n/a |
| Vogenx Inc · NASDAQ:VOGX | US$176.3M | US$94.21M | n/a | n/a | n/a | 2.1× | n/a | 0.0× | n/a |
| MediWound Ltd. · NASDAQ:MDWD | US$175.5M | US$155.9M | n/a | 15.6× | n/a | 5.5× | −235.0% | 0.3× | 0.64 |
| Nanexa AB · OMXSTO:NANEXA | US$175.1M | US$170.1M | n/a | 51.4× | n/a | 13.5× | −72.5% | 0.0× | n/a |
| Compugen Ltd. · NASDAQ:CGEN | US$174.3M | US$59.55M | 4.8× | 0.8× | n/a | 2.1× | 47.9% | 0.0× | 1.49 |
| Median of the others | US$180.6M | US$110.2M | 4.8× | 15.6× | 2.1× | −174.9% | 0.0× | 1.35 |
Forecasts
8 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.75 · 10 analysts
- Revenue, year to Dec 2026
- 1.74M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ram Aiyar | Chief Executive Officer & President |
| Todd Chappell | Chief Operating Officer |
| Jeffrey M. Cerio | SVP, General Counsel |
| Gaozhong Zhu | SVP, CMC & Technical Operations |
| Jean-François Formela | Co-Founder & Director |
| Loïc Vincent | Chief Scientific Officer |
| Nessan Bermingham | Co-Founder & Chairman |
| Stephanie Engels | Chief People Officer |
Board
| Director | Role |
|---|---|
| Nessan Bermingham | Co-Founder & Chairman |
| Ali Behbahani | Director |
| Jean-François Formela | Co-Founder & Director |
| Katharine Knobil | Director |
| Rachel Meyers | Director |
| Ram Aiyar | Chief Executive Officer & President |
| Timothy R. Pearson | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −11.4% |
| Q2 2026 | Aug 6, 2026 · Before open | +5.4% |
| Q1 2026 | May 7, 2026 | −9.7% |
| Q4 2025 | Mar 12, 2026 · After close | +11.3% |
| Q3 2025 | Nov 12, 2025 · After close | −79.3% |
| Q2 2025 | Aug 12, 2025 · Before open | +6.3% |
| Q1 2025 | May 7, 2025 · After close | +10.6% |
| Q4 2024 | Mar 24, 2025 · Before open | +1.1% |
| Q3 2024 | Nov 12, 2024 · After close | −15.6% |
| Q2 2024 | Aug 13, 2024 · After close | +9.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | +5.4% |
| Q4 2023 | Mar 26, 2024 · After close | +1.8% |
| Q3 2023 | Nov 2, 2023 · After close | +6.0% |
| Q2 2023 | Aug 10, 2023 | −4.1% |
| Q1 2023 | May 12, 2023 | −5.6% |
| Q4 2022 | Mar 10, 2023 | +3.1% |
| Q3 2022 | Nov 8, 2022 | −5.8% |
| Q2 2022 | Aug 9, 2022 | −3.1% |
| Q1 2022 | May 4, 2022 | +1.6% |
| Q4 2021 | Mar 15, 2022 | +29.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 26 slides | August 2026 |
| Investor Presentation (May 2026) | Investor deck | 5 slides | May 19, 2026 |
| Investor Day (January 2026) | Investor day | 54 slides | Jan 27, 2026 |
| Investor Day (January 2026) | Investor day | 32 slides | Jan 27, 2026 |
| J.P. Morgan Healthcare Conference 2024 | Conference | 36 slides | Jan 9, 2024 |
| Merger or Acquisition (July 2023) | Merger or acquisition | 30 slides | July 2023 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.39M | 2.27M | 0 | 0 | 14.1M | 37.0M | 28.9M | ||
| Cost of revenue | 4.28M | 3.56M | 3.63M | 2.51M | 3.84M | 1.58M | 16.8M | 654.0K | 531.0K |
| Gross profit | 2.11M | 2.27M | -3.63M | -2.51M | 10.2M | 35.4M | 12.1M | -654.0K | -531.0K |
| Research and development | 65.6M | 63.6M | 57.3M | 42.2M | 60.9M | 37.4M | 18.8M | 11.9M | 12.0M |
| Selling, general and administrative | 28.2M | 30.5M | 24.0M | 16.8M | 11.7M | ||||
| Operating income | -121.9M | -91.9M | -84.5M | -59.0M | -84.0M | -27.6M | -20.7M | -18.9M | -16.3M |
| Depreciation and amortization | 4.28M | 3.56M | 3.63M | 2.51M | 2.77M | 1.15M | 813.0K | 654.0K | 531.0K |
| EBITDA | -117.6M | -88.3M | -80.9M | -56.5M | -81.3M | -26.4M | -19.9M | -18.3M | -15.8M |
| Interest expense | 961.0K | 764.0K | 0 | 106.0K | 174.0K | ||||
| Income before tax | -116.6M | -83.4M | -81.1M | -58.0M | -84.7M | -26.5M | -18.7M | -19.2M | -20.2M |
| Income tax | 637.0K | 141.0K | 27.0K | 10.0K | 15.0K | 35.0K | 0 | 1 | |
| Net income | -117.3M | -83.6M | -81.2M | -58.0M | -84.7M | -26.5M | -18.7M | -19.2M | -20.2M |
| Earnings per share, basic | -12.48 | -9.37 | -53.08 | -227.42 | -2.47 | -0.82 | -2.29 | -12.53 | -28.79 |
| Earnings per share, diluted | -12.48 | -9.37 | -53.08 | -227.42 | -2.47 | -0.82 | -2.29 | -12.53 | -28.79 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 21.8M | 55.6M | 166.2M | 36.3M | 79.6M | 220.3M | 200.2M | 42.2M | 17.9M |
| Short-term investments | 53.3M | 70.5M | 0 | 18.9M | 51.1M | 17.2M | |||
| Receivables | 969.0K | 1.70M | 0 | 449.0K | 144.0K | 340.0K | 805.0K | 161.0K | |
| Inventory | -144.0K | ||||||||
| Current assets | 82.4M | 131.5M | 172.7M | 57.1M | 134.7M | 225.1M | 221.4M | 42.9M | 18.0M |
| Property, plant and equipment | 8.16M | 27.7M | 15.7M | 9.87M | 5.52M | 7.29M | 1.76M | 1.51M | |
| Total assets | 113.5M | 226.2M | 221.7M | 73.7M | 185.4M | 264.7M | 223.2M | 44.5M | 19.8M |
| Accounts payable | 1.65M | 3.99M | 7.28M | 2.60M | 2.75M | 5.51M | 1.22M | 1.86M | 994.0K |
| Current liabilities | 11.9M | 15.0M | 19.5M | 8.70M | 11.4M | 26.6M | 52.8M | 3.77M | 2.23M |
| Long-term debt | 180.0K | 349.0K | |||||||
| Total debt | 43.5M | 44.8M | 33.2M | 10.0M | 833.0K | 46.0M | 180.0K | 349.0K | 46.7M |
| Total liabilities | 62.1M | 65.8M | 51.8M | 8.91M | 54.5M | 72.2M | 55.9M | 4.12M | 49.4M |
| Shareholders' equity | 51.4M | 160.4M | 169.9M | -99.0M | -42.2M | 192.5M | 167.4M | -48.3M | -29.6M |
| Shares outstanding | 9.42M | 9.38M | 8.02M | 268.5K | 34.6M | 34.0M | 30.8M | 2.08M | 30.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -78.6M | -60.1M | -67.3M | -53.6M | -76.1M | -45.2M | 34.2M | -17.0M | -14.6M |
| Capital spending | -518.0K | -17.9M | -7.84M | -5.14M | -2.91M | -6.67M | -1.06M | -436.0K | -1.86M |
| Free cash flow | -79.1M | -78.0M | -75.1M | -58.8M | -79.0M | -51.9M | 33.2M | -17.5M | -16.5M |
| Cash from investing | 44.0M | -123.3M | 11.2M | 11.1M | -66.1M | 10.4M | -18.3M | -436.0K | -1.86M |
| Cash from financing | 685.0K | 69.4M | 187.8M | 18.0K | 1.36M | 56.7M | 142.0M | 41.7M | 28.0M |
| Change in cash | -33.8M | -114.1M | 131.6M | -42.6M | -140.8M | 21.9M | 158.0M | 24.3M | 11.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 12, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 22, 2026 | Current report | SEC |
| 8-K · Current report | Oct 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 14, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 19, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 19, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 4, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 29, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 8-K · Current report | May 19, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 16, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 23, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Mar 20, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 18, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 18, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 17, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Mar 13, 2026 | Offer document | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 12, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 27, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 27, 2026 | Current report | SEC |
| 8-K · Current report | Jan 15, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 18, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Oct 8, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 8-K/A · Current report, amended | Jun 18, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 27, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Feb 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 11, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 424B3 · Prospectus | Dec 10, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 10, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 10, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 10, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 9, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Dec 6, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 6, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 6, 2024 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Dec 2, 2024 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Dec 2, 2024 | Offer document | SEC |
| S-3 · Registration statement | Dec 2, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 21, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 21, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 21, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 12, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 12, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 12, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Nov 4, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 4, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 17, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Sep 16, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Sep 16, 2024 | Offer document | SEC |
This page holds 200 of 836 filings. Open Filings
Cap table
Built by 6ix from Korro Bio, Inc.’s releases · as of Nov 11, 2026
- Common shares
- 14,725,646
- Fully diluted
- 14,726,646
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 14,725,646 | |
| Options and RSUs | 1,000 | Nov 11, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$14.41 · expire about Nov 2036 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 14,725,646 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ali Behbahani Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past) | Director · Since at least Nov 3, 2023 |
| Jean-François Formela Other companies: ImageneBio, Inc. (Director · Mar 25, 2021 – Jun 7, 2024 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Spero Therapeutics, Inc. (Director · Nov 1, 2017 – Aug 17, 2021 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past); Oruka Therapeutics, Inc. (Director · Feb 10, 2012 – Oct 22, 2012 · Past); Horizon Pharma PLC (Director · Jul 28, 2011 – Mar 2, 2012 · Past) | Co-Founder & Director · Since at least Nov 3, 2023 |
| Robert Langer Other companies: Seer, Inc. (Director · Since at least Dec 3, 2020); Lyra Therapeutics, Inc. (David H. Koch Institute Professor, Massachusetts Institute of Technology · Since at least Apr 30, 2020); Moderna, Inc. (Director · Dec 7, 2018 – May 6, 2024 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – Oct 14, 2019 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 12, 2018 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 21, 2016 · Past); Ocata Therapeutics Inc (Director · Oct 4, 2011 – Feb 10, 2016 · Past) | Director · Oct 2, 2019 – Aug 17, 2022 · Past |
| Peter P Pfreundschuh Other companies: Y mAbs Therapeutics (EVP, CFO and Treasurer · Since at least Jun 28, 2024); Voyager Therapeutics, Inc. (Chief Financial Officer · Sep 19, 2022 – Feb 21, 2024 · Past); UroGen Pharma Ltd. (Chief Financial Officer · Jan 1, 2019 – Oct 15, 2020 · Past); Sucampo Pharmaceuticals Inc (CFO · Mar 20, 2017 – Feb 13, 2018 · Past); Immunomedics Inc (Chief Financial Officer · Aug 20, 2015 – Aug 20, 2015 · Past) | Chief Financial Officer · Dec 1, 2020 – Feb 18, 2022 · Past |
| Marc Cohen Other companies: C4 Therapeutics, Inc. (In MemoriamCo-Founder & Executive Chairman Emeritus · Since at least Oct 1, 2020) | Director · Oct 2, 2019 – Jun 21, 2022 · Past |
| Michael Bookman Other companies: Immuneering Corporation (Chief Legal Officer, Secretary · Since at least Jul 29, 2021) | General Counsel and Secretary · Jan 19, 2021 – Apr 20, 2021 · Past |
| Dana Charles Hilt | Chief Medical Officer · Oct 2, 2019 – Apr 20, 2021 · Past |
| David L Lucchino | Director · Oct 2, 2019 – Jun 11, 2024 · Past |
| Gaozhong Zhu | SVP, CMC & Technical Operations · Since at least Apr 1, 2025 |
| Jeffrey M. Cerio | SVP, General Counsel · Since at least Nov 12, 2024 |
All 21 people
| Person | Seat |
|---|---|
| Katharine Knobil | Director · Since at least Nov 12, 2024 |
| Loïc Vincent | Chief Scientific Officer · Since at least Mar 31, 2025 |
| Nessan Bermingham | Co-Founder & Chairman · Since at least Nov 4, 2026 |
| Oliver Dolan | Senior Vice President, Finance · Since at least Feb 11, 2025 |
| Quentin McCubbin | Chief Manufacturing Officer · Jan 19, 2021 – Jan 26, 2023 · Past |
| Rachel Meyers | Director · Since at least Nov 4, 2026 |
| Ram Aiyar | President and CEO, Director · Since at least Nov 3, 2023 |
| Stephanie Engels | Chief People Officer · Since at least Nov 4, 2026 |
| Timothy R. Pearson | Director · Since at least Nov 4, 2026 |
| Todd Chappell | Chief Operating Officer · Since at least Nov 3, 2023 |
| Vineet Agarwal | Chief Financial Officer · Nov 3, 2023 – Feb 3, 2025 · Past |
Log in to ask 6ix AI your own questions about Korro Bio, Inc.